MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,342 Shares of United Therapeutics Co. (NASDAQ:UTHR)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 26.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,446 shares of the biotechnology company's stock after buying an additional 1,342 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.'s holdings in United Therapeutics were worth $2,281,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Investment Management Corp of Ontario increased its position in United Therapeutics by 157.2% in the fourth quarter. Investment Management Corp of Ontario now owns 29,904 shares of the biotechnology company's stock worth $10,551,000 after buying an additional 18,278 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of United Therapeutics by 1.9% during the fourth quarter. Janus Henderson Group PLC now owns 468,996 shares of the biotechnology company's stock worth $165,490,000 after purchasing an additional 8,577 shares in the last quarter. Hudson Bay Capital Management LP grew its position in shares of United Therapeutics by 98.0% during the fourth quarter. Hudson Bay Capital Management LP now owns 70,319 shares of the biotechnology company's stock worth $24,811,000 after purchasing an additional 34,810 shares in the last quarter. Gotham Asset Management LLC grew its position in shares of United Therapeutics by 17.5% during the fourth quarter. Gotham Asset Management LLC now owns 61,179 shares of the biotechnology company's stock worth $21,586,000 after purchasing an additional 9,121 shares in the last quarter. Finally, Focus Partners Wealth grew its position in shares of United Therapeutics by 127.1% during the fourth quarter. Focus Partners Wealth now owns 1,917 shares of the biotechnology company's stock worth $679,000 after purchasing an additional 1,073 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on UTHR shares. Morgan Stanley increased their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price for the company in a research report on Monday, April 21st. Wall Street Zen cut United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a research report on Friday, April 25th. Finally, JPMorgan Chase & Co. cut their target price on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a research report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $392.00.

Insider Activity

In other news, Director Raymond Dwek sold 4,000 shares of the firm's stock in a transaction that occurred on Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the sale, the director now directly owns 1,750 shares of the company's stock, valued at $497,962.50. This trade represents a 69.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total value of $3,367,980.00. Following the completion of the sale, the executive vice president now directly owns 36,781 shares of the company's stock, valued at $11,261,606.58. The trade was a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 45,500 shares of company stock valued at $13,447,180 in the last ninety days. Insiders own 10.30% of the company's stock.

United Therapeutics Stock Up 2.3%

NASDAQ UTHR traded up $7.19 during trading on Tuesday, hitting $314.84. 494,141 shares of the stock traded hands, compared to its average volume of 442,934. The company has a market capitalization of $14.20 billion, a P/E ratio of 13.83, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. The firm has a 50-day simple moving average of $299.44 and a 200-day simple moving average of $336.59. United Therapeutics Co. has a 12-month low of $264.33 and a 12-month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter last year, the business posted $6.17 EPS. As a group, research analysts predict that United Therapeutics Co. will post 24.48 EPS for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.